Trastuzumab deruxtecan

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer

NCT04482309

Clinical

Trials by Indication[1]

Breast Cancer8 trials

REal-world Study of Trastuzumab deruXtecan in Patients With unresectabLe or Metastatic Breast Cancer Expressing HER2-lOw From BulgaRia and SlovEnia (EXPLORE)

Recruiting· AstraZeneca logo

AstraZeneca··NCT06727227·138 enrolled

Aprospective, Multi Center Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, an Anti-her2-antibody Drug Conjugate in Indian Patients With Unresectable or Metastatic her2-positive Breast Cancer Who Have Received a Prior Anti-her2-based Regimen

Active, not recruiting· AstraZeneca logo

AstraZeneca·Approved·NCT06429761·100 enrolled

A Phase II Non-comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-negative (HER2-low or HER2-0) Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy

Recruiting·AAna C Garrido-Castro, MD·Phase 2·NCT06533826·357 enrolled

Show 5 more trials

A Prospective, Multicenter, Single-Arm Study Verifying the Benefit of Trastuzumab Deruxtecan (T-DXd) in AI Re-Scored HER2-Ultralow (HER2UL) Unresectable or Metastatic Breast Cancer Manually Scored as HER2-Null

Not yet recruiting·SShuangyue Liu·Preclinical·NCT07782086·30 enrolled

Phase 1b Study Of Allogeneic CAR TROP2/IL15 Transduced TGFBR2 KO CB NK-Cells (TRICK-NK) In Combination With Trastuzumab Deruxtecan (T-Dxd) In Treatment-Refractory Breast Cancers

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07553390·60 enrolled

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04739761·506 enrolled

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05633979·17 enrolled

Phase II Trial Evaluating Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer (MBC)

Not yet recruiting·WWashington University School of Medicine·Phase 2·NCT07619365·60 enrolled

Metastatic Breast Cancer3 trials

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination With Other Agents for the Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC), Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC), or Metastatic Colorectal Cancer (mCRC)

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Preclinical·NCT06324357·768 enrolled

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

Recruiting· Roche logo

Roche·Preclinical·NCT03424005·1,132 enrolled

A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT04556773·138 enrolled

HER2-positive Gastric Cancer2 trials

A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06764875·840 enrolled

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China: A Nation-wide, Multi-center, Prospective, Non-interventional Study

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo··NCT06846996·260 enrolled

Metastatic Malignant Solid Neoplasm2 trials

A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT04585958·55 enrolled

Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05372614·58 enrolled

Endometrial Cancer2 trials

DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06989112·600 enrolled

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT07022483·710 enrolled

34 more indications

Breast Neoplasms2 trials

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07060807·1,000 enrolled

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05113251·927 enrolled

Gastric Cancer2 trials

A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT04379596·452 enrolled

A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT06731478·726 enrolled

Unresectable Breast Cancer2 trials

A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-(Ultra)Low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-(Ultra)Low Europe)

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo··NCT05945732·2,295 enrolled

Real World Study of TrEatment Discontinuations and Modifications for Patients With HER2+ and HER2-low Metastatic Breast Cancer On Trastuzumab Deruxtecan

Completed· AstraZeneca logo

AstraZeneca··NCT06386263·22 enrolled

Advanced Breast Cancer2 trials

A Randomized Phase II Study to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan Versus CDK4/6 Inhibitor-based Endocrine Therapy as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype According to Gene Expression Profiling.

Recruiting·MMedSIR·Phase 2·NCT06486883·200 enrolled

A Global, Interventional, Open-label Trial of T-DXd-based Therapy Followed by Palbociclib, Endocrine Therapy and Dual HER2 Blockade in First-line HER2+/ HR+ Advanced or Metastatic Breast Cancer and Retreatment With T-DXd (DB-Guide)

Not yet recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT07683754·200 enrolled

Metastatic Pancreatic Adenocarcinoma1 trial

An Umbrella Clinical Trial of Antibody/Peptide-Drug Conjugates Matched by Mass Spectrometry-Based Absolute Quantitation of Proteins in Locally Advanced or Metastatic Pancreatic or Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07825753·225 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT06899126·686 enrolled

Colorectal Cancer1 trial

Window-of-opportunity Umbrella Platform Trial of Short-course Pre-operative Targeted Treatments in Patients With Molecularly Selected and Resectable Primary Colorectal Cancer: the UNICORN Study

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT05845450·197 enrolled

Desmoplastic Small Round Cell Tumor1 trial

A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04616560·55 enrolled

Advanced Breast Carcinoma1 trial

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04704661·51 enrolled

Advanced Malignant Solid Neoplasm1 trial

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06311214·500 enrolled

Locally Advanced Lung Non-Small Cell Carcinoma1 trial

A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib Plus Trastuzumab Deruxtecan in Patients With Advanced Non-Small Cell Lung Cancer With a KRASG12C Mutation

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07012031·37 enrolled

Clinical Stage III Gastric Cancer AJCC v81 trial

Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06364410·48 enrolled

Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)1 trial

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) as Monotherapy or in Combination With Anti-cancer Agents for the Treatment of Patients With Selected HER2-expressing Tumors (DESTINY PanTumor03)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06271837·127 enrolled

Breast Cancer Metastatic1 trial

Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer

Recruiting·YYale University·Phase 2·NCT06750484·40 enrolled

Adenocarcinoma (NOS)1 trial

Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study

Recruiting· AstraZeneca logo

AstraZeneca··NCT07124000·100 enrolled

Advanced Malignancies1 trial

Study of Efficacy and Toxicity of Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer Patients: Single Center Experience, Madinah, Saudi Arabia

Completed·MMansoura University··NCT07778407·25 enrolled

HER2-positive Advanced Gastric Cancer1 trial

A Prospective Non-interventional Study (NIS) of Trastuzumab DeRuxtecan (T-DXd) for Adult Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction (GEJ) AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen, Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies in a Real-world Setting in Europe (PROSPERITY)

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo··NCT05993234·257 enrolled

Urinary Bladder Neoplasms1 trial

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT05614739·677 enrolled

Biliary Tract Cancer1 trial

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06467357·620 enrolled

Non-Small Cell Lung Carcinoma1 trial

An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After at Least One-line of Treatment (DESTINY-Lung05)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05246514·72 enrolled

Metastatic Salivary Gland Carcinoma1 trial

A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Recruiting·NNRG Oncology·Phase 2·NCT05408845·146 enrolled

Gastroesophageal Adenocarcinoma1 trial

A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07069712·100 enrolled

Advanced Solid Malignancies1 trial

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT05417594·695 enrolled

Breast Cancer Female1 trial

A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study

Recruiting·DDana-Farber Cancer Institute·Phase 2·NCT06439693·72 enrolled

Triple Negative Breast Neoplasms1 trial

A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT03742102·243 enrolled

Breast Cancer; HER2-positive; Metastatic1 trial

Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04784715·1,157 enrolled

Hormone Receptor Positive1 trial

A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With Trastuzumab Deruxtecan (T-DXd) in Participants With Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer (HERTHENA-Breast02)

Not yet recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Preclinical·NCT07701941·220 enrolled

Anatomic Stage III Breast Cancer AJCC v81 trial

Phase 1b Study of Pidnarulex and Trastuzumab Deruxtecan in Patients With HER2 Expressing Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT07137416·36 enrolled

Locally Advanced or Metastatic Non-small Cell Lung Cancer1 trial

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05048797·454 enrolled

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer1 trial

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT04482309·477 enrolled

Recurrent or Metastatic Solid Tumors1 trial

A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT07015697·76 enrolled

Ovarian Cancer1 trial

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT06819007·582 enrolled

Stomach Neoplasms1 trial

A Phase II Platform Trial of Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (Neo-VIKTORY)

Recruiting·JJeeyun Lee·Phase 2·NCT06630130·100 enrolled

Anatomic Stage IV Breast Cancer AJCC v81 trial

Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab Deruxtecan

Recruiting·CCity of Hope Medical Center·Approved·NCT05376878·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 55 trial records for Trastuzumab deruxtecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Trastuzumab deruxtecan. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate
Highest Phase: Phase 3[1]
Company: AstraZeneca

Trastuzumab deruxtecan

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Breast Cancer8 trials

Metastatic Breast Cancer3 trials

HER2-positive Gastric Cancer2 trials

Metastatic Malignant Solid Neoplasm2 trials

Endometrial Cancer2 trials

Breast Neoplasms2 trials

Gastric Cancer2 trials

Unresectable Breast Cancer2 trials

Advanced Breast Cancer2 trials

Metastatic Pancreatic Adenocarcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Colorectal Cancer1 trial

Desmoplastic Small Round Cell Tumor1 trial

Advanced Breast Carcinoma1 trial

Advanced Malignant Solid Neoplasm1 trial

Locally Advanced Lung Non-Small Cell Carcinoma1 trial

Clinical Stage III Gastric Cancer AJCC v81 trial

Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)1 trial

Breast Cancer Metastatic1 trial

Adenocarcinoma (NOS)1 trial

Advanced Malignancies1 trial

HER2-positive Advanced Gastric Cancer1 trial

Urinary Bladder Neoplasms1 trial

Biliary Tract Cancer1 trial

Non-Small Cell Lung Carcinoma1 trial

Metastatic Salivary Gland Carcinoma1 trial

Gastroesophageal Adenocarcinoma1 trial

Advanced Solid Malignancies1 trial

Breast Cancer Female1 trial

Triple Negative Breast Neoplasms1 trial

Breast Cancer; HER2-positive; Metastatic1 trial

Hormone Receptor Positive1 trial

Anatomic Stage III Breast Cancer AJCC v81 trial

Locally Advanced or Metastatic Non-small Cell Lung Cancer1 trial

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer1 trial

Recurrent or Metastatic Solid Tumors1 trial

Ovarian Cancer1 trial

Stomach Neoplasms1 trial

Anatomic Stage IV Breast Cancer AJCC v81 trial

References

Drug Info

Quick Facts

Related News